STOCK TITAN
  1. Home
  2. News
  3. GILD

Gilead Sciences Inc - GILD STOCK NEWS

Welcome to our dedicated page for Gilead Sciences news (Ticker: GILD), a resource for investors and traders seeking the latest updates and insights on Gilead Sciences stock.

Gilead Sciences, Inc. is an American biopharmaceutical company based in Foster City, California. The company specializes in researching, developing, and marketing antiviral drugs used in the treatment of a variety of viral infections including HIV/AIDS, hepatitis B and C, influenza, and COVID-19. Gilead is renowned for its innovative approach to creating life-saving therapies, with a core focus on diseases such as HIV and hepatitis. Some of its groundbreaking products include ledipasvir/sofosbuvir and sofosbuvir, pivotal in the treatment of hepatitis C.

Gilead's extensive portfolio has been significantly enhanced through strategic acquisitions. The purchase of Corus Pharma, Myogen, CV Therapeutics, Arresto Biosciences, and Calistoga has allowed the company to diversify into pulmonary and cardiovascular diseases and cancer treatments. The acquisition of Pharmasset was particularly notable, providing Gilead with the rights to the hepatitis C drug Sovaldi, further combined into the drug Harvoni. Additionally, Gilead has expanded its oncology offerings through the acquisitions of Kite, Forty Seven, and Immunomedics, strengthening its position in both cell therapy and non-cell therapy in oncology.

Gilead continually seeks to innovate and push the boundaries of medicine to offer better therapeutic solutions. Recent projects include expanding its antiviral pipeline and exploring novel treatments for various cancers. Financially, Gilead remains robust, with substantial investments in research and development to drive future growth and maintain its leadership in the biopharmaceutical industry.

News

How Gilead’s Pharmaceutical Development and Manufacturing Team Delivers Transformative Medicines

Rhea-AI Summary
Gilead Sciences' Pharmaceutical Development and Manufacturing (PDM) team plays a key role in creating and delivering medicines. They ensure an adequate and high-quality supply during clinical trials and after product approval. PDM's innovation in manufacturing technology contributes to Gilead's success.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
0.9%
Tags
none
-
News

Gilead Announces Partial Clinical Hold for Magrolimab Studies in AML

Rhea-AI Summary
FDA places partial clinical hold on new patients in Gilead's magrolimab AML studies
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
0.08%
Tags
none
-
News

Gilead Sciences and Meharry Medical College Highlight Five-Year Impact of Gilead COMPASS Initiative® on HIV in the Southern United States

Rhea-AI Summary
Gilead Sciences and Meharry Medical College publish a supplemental issue detailing the impact of the Gilead COMPASS Initiative in addressing the HIV epidemic in the Southern United States.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-0.81%
Tags
none
News

Gilead’s Focus on Ending the HIV Epidemic for Children Everywhere

Rhea-AI Summary
Gilead Sciences is partnering with clinicians to develop advanced and accessible therapies for children living with HIV. Currently, only 54% of children with HIV are on antiretroviral therapy compared to 74% of adults. Gilead aims to close this treatment gap by developing innovative therapies and improving medication accessibility. They have opened the global Pediatric Centre of Excellence in Dublin to coordinate pediatric clinical trials and are collaborating to create dispersible medications for children. Long-acting injectable medications are also being explored as a potential solution. Closing the treatment gap for children is crucial in ending the HIV epidemic.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-2.06%
Tags
none
-
News

Gilead and Tentarix to Discover and Develop Novel Therapies to Address Unmet Medical Needs Across Cancer and Inflammation

Rhea-AI Summary
GILD: Gilead Sciences and Tentarix Biotherapeutics Collaborate to Develop Novel Therapies for Oncology and Inflammatory Diseases, Gilead to Acquire Exclusive Rights. Tentarix to Receive $66 Million in Upfront Payments and Equity Investment from Gilead
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-0.26%
Tags
none
-
News

Gilead Sciences: A Cut Above the Rest: Innovative Barbershop Program Educates Indigenous Men About HIV

Rhea-AI Summary
Gilead Sciences (GILD) announces a new educational initiative to raise awareness about HIV prevention and treatment. The company will provide resources and support for at-risk communities, emphasizing the importance of early intervention and access to care. This initiative aligns with Gilead's commitment to public health and social responsibility, showcasing their leadership in the pharmaceutical industry.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
0.11%
Tags
none
News

Gilead Sciences Announces Second Quarter 2023 Financial Results

Rhea-AI Summary
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
4.17%
Tags
earnings
-
News

Gilead Sciences Announces Its Largest Commitment to Health Equity for Australian and Canadian Indigenous Communities

Rhea-AI Summary
Gilead Sciences Inc. announces a $6 million grant program to support health equity for Australian and Canadian Indigenous communities. The program aims to address disparities in health outcomes related to HIV and viral hepatitis. Gilead is partnering with Indigenous-led organizations to fund culturally appropriate solutions.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-- %
Tags
none
-
News

European Commission Approves Gilead’s Trodelvy® For Pre-Treated HR+/HER2- Metastatic Breast Cancer

Rhea-AI Summary
Gilead Sciences receives European Commission approval for Trodelvy as a monotherapy for the treatment of HR-positive, HER2-negative breast cancer. The approval is based on the Phase 3 TROPiCS-02 study, which showed a statistically significant overall survival benefit and a reduction in disease progression or death. Trodelvy could replace standard chemotherapy and provide a new treatment option for patients.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-0.88%
Tags
none
News

Twice-Yearly Lenacapavir Demonstrates Sustained Impact on Health-Related Quality of Life in People With HIV

Rhea-AI Summary
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-0.55%
Tags
none

FAQ

What is the current stock price of Gilead Sciences (GILD)?

The current stock price of Gilead Sciences (GILD) is $90.19 as of November 22, 2024.

What is the market cap of Gilead Sciences (GILD)?

The market cap of Gilead Sciences (GILD) is approximately 111.8B.

What is Gilead Sciences, Inc.?

Gilead Sciences is an American biopharmaceutical company that focuses on developing antiviral drugs for diseases like HIV, hepatitis B and C, influenza, and COVID-19.

Where is Gilead Sciences headquartered?

Gilead Sciences is headquartered in Foster City, California.

What are some key products of Gilead Sciences?

Some key products include ledipasvir/sofosbuvir and sofosbuvir for hepatitis C treatment and several innovative antiviral therapies.

Which companies has Gilead Sciences acquired?

Gilead has acquired companies such as Corus Pharma, Myogen, CV Therapeutics, Arresto Biosciences, Calistoga, Pharmasset, Kite, Forty Seven, and Immunomedics.

What diseases does Gilead Sciences' portfolio cover?

Gilead's portfolio covers life-threatening diseases like HIV, hepatitis B and C, pulmonary and cardiovascular diseases, influenza, and various cancers.

How has Gilead expanded its oncology offerings?

Gilead has bolstered its oncology portfolio through acquisitions of Kite, Forty Seven, and Immunomedics, enhancing its cell therapy and non-cell therapy options.

What is Gilead's financial condition?

Gilead maintains a strong financial position with significant investments in research and development to support ongoing growth and innovation.

What is Gilead's approach to research and development?

Gilead focuses on continual innovation and investment in R&D to develop groundbreaking treatments for viral infections and other serious diseases.

What recent projects is Gilead working on?

Gilead is currently working on expanding its antiviral drug pipeline and exploring new treatments for various types of cancer.

Where can I find the latest news about Gilead Sciences?

You can find the latest updates and news about Gilead Sciences on their official website and through reliable financial news sources.

Stock GILD logo
Gilead Sciences Inc

NYSE:GILD

GILD Rankings

#114 Ranked by Market Cap
#873 Ranked by Dividends

GILD Stock Data

111.79B
1.24B
0.12%
88.41%
1.42%
Drug Manufacturers - General
Biological Products, (no Disgnostic Substances)
Link
United States of America
FOSTER CITY